This study therefore establishes that the 41BB-agonist potentiates the efficacy of IRE+Combo-therapy for lung cancer treatment by promoting both TRM and cDC1 responses, and emphasizes the importance of targeting this promising molecular signal to improve current IRE-ablation protocols for lung cancer or other solid malignancies such as liver, colon and stomach cancers. The gene discussed is MPPE1; the disease is gastric neoplasm.